The Actavis Group has received approval to market generic ranitidine oral solution USP in the 15-mg/mL strength. This product is the generic equivalent of GlaxoSmithKline’s Zantac drug Syrup. Ranitidine is indicated for the treatment and prevention of ulcers and gastroesoph-ageal reflux disease (GERD) and for the treatment of conditions caused by high acid secretion.

Random Posts:

• NDA Withdrawn for Pancreatic Cancer Drug
• Risky Glaucoma Treatment
• A New Complication of Thalidomide Therapy
• Cancer Warnings Required For Anti-inflammatory Drugs
• Tysabri: New Brain Infections Result in a Safety Update